TB-500 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-30. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
=== Barrier properties === In semi-crystalline polymers, the crystalline regions are considered to be gas impermeable. Due to relatively high crystallinity, in combination with the ability of the nanofibers to form a dense network held together by strong inter-fibrillar bonds (high cohesive energy density), it has been suggested that nanocellulose might act as a barrier material. Although the number of reported oxygen permeability values are limited, reports attribute high oxygen barrier properties to nanocellulose films. One study reported an oxygen permeability of 0.0006 (cm3 μm)/(m2 day kPa) for a ca. 5 μm thin nanocellulose film at 23 °C and 0% RH. In a related study, a more than 700-fold decrease in oxygen permeability of a polylactide (PLA) film when a nanocellulose layer was added to the PLA surface was reported. The influence of nanocellulose film density and porosity on film oxygen permeability has been explored. Some authors have reported significant porosity in nanocellulose films, which seems to be in contradiction with high oxygen barrier properties, whereas Aulin et al. measured a nanocellulose film density close to density of crystalline cellulose (cellulose Iß crystal structure, 1.63 g/cm3) indicating a very dense film with a porosity close to zero. Changing the surface functionality of the cellulose nanoparticle can also affect the permeability of nanocellulose films. Films constituted of negatively charged CNCs could effectively reduce permeation of negatively charged ions, while leaving neutral ions virtually unaffected.
== June 27, 1915 (Sunday) == Born: Grace Lee Boggs, American author and social activist, author of The Invading Socialist Society and The Next American Revolution; as Grace Chin Lee, in Providence, Rhode Island, United States (d. 2015)
subunit A single unit of a multi-unit compound or molecular aggregate; e.g. a monomer from which a larger polymer is composed (as with nucleotides in nucleic acids), or an individual polypeptide chain in a multi-chain protein, or an entire protein which participates alongside other proteins as part of a protein complex.
Carbon nanotubes are thus being explored as interconnects and conductivity-enhancing components in composite materials, and many groups are attempting to commercialize highly conducting electrical wire assembled from individual carbon nanotubes. There are significant challenges to be overcome however, such as undesired current saturation under voltage, and the much more resistive nanotube-to-nanotube junctions and impurities, all of which lower the electrical conductivity of the macroscopic nanotube wires by orders of magnitude, as compared to the conductivity of the individual nanotubes. Because of its nanoscale cross-section, electrons propagate only along the tube's axis. As a result, carbon nanotubes are frequently referred to as one-dimensional conductors. The maximum electrical conductance of a single-walled carbon nanotube is 2G0, where G0 = 2e2/h is the conductance of a single ballistic quantum channel. Because of the role of the π-electron system in determining the electronic properties of graphene, doping in carbon nanotubes differs from that of bulk crystalline semiconductors from the same group of the periodic table (e.g., silicon). Graphitic substitution of carbon atoms in the nanotube wall by boron or nitrogen dopants leads to p-type and n-type behavior, respectively, as would be expected in silicon. However, some non-substitutional (intercalated or adsorbed) dopants introduced into a carbon nanotube, such as alkali metals and electron-rich metallocenes, result in n-type conduction because they donate electrons to the π-electron system of the nanotube.
Sources: en.wikipedia.org
=== Approved drugs === Emoxypine (ethylmethylhydroxypyridine; Mexidol) – antioxidant and unknown mechanism of action [135] Tandospirone (metanopirone; Sediel; SM-3997) – serotonin 5-HT1A receptor partial agonist [136] Tianeptine (Coaxil; Stablon; Tatinol) – weak atypical μ-opioid receptor agonist and other actions [137]
== Selective Ligands == Neuromedin U is an agonist at both the NMU1 and NMU2 subtypes, while neuromedin S is selective for NMU2, and is a more potent agonist at this subtype than neuromedin U. Several other peptide and non-peptide ligands are also available for the NMU receptors.
== Chemistry == Mycosporine–like amino acids are rather small molecules (<400 Da). The structures of over 30 MAAs have been resolved and all contain a central cyclohexenone or cyclohexenimine ring and a wide variety of substitutions. The ring structure is thought to absorb UV light and accommodate free radicals. All MAAs absorb ultraviolet wavelengths, typically between 310 and 362 nm. They are considered to be amongst the strongest natural absorbers of UV radiation. It is this light absorbing property that allows MAAs to protect cells from the harmful UV-B and UV-A components of sunlight. Biosynthetic pathways of MAAs depend on the specific MAA molecule and the organism that is producing it. These biosynthetic pathways often share common enzymes and metabolic intermediates with pathways of the primary metabolism. An example is the shikimate pathway that is classically used to produce the aromatic amino acids (phenylalanine, tyrosine and tryptophan); with many intermediates and enzymes from this pathway utilized in MAA biosynthesis.
The same Stictis fungus can form a lichen when algae are present (it was formerly classified in a separate lichen genus, Conotrema) or live as a saprobe (decay organism) when absent—yet in both cases it retains the same Latin name. These cases underscore that the mycobiont is the nomenclatural unit; the lichen is its ecological expression. The holobiont lens nonetheless shifts research toward how fungal–algal–microbial associations evolve. Topics such as photobiont switching—common among closely related Trebouxia strains but rare between major algal lineages—are tested for links with adaptation and speciation. Photobiont flexibility — a fungus's ability to switch algal partners — appears to vary. Many lichen-forming fungi can pair with multiple algae of the same general type (for example, different strains of Trebouxia, a genus of green algae). However, switching to a completely different type of algal partner (say, from a green alga to a cyanobacterium) is much rarer, and often coincides with a major evolutionary shift in the lichen.
The only drug currently approved for stroke treatment is tPA, which can cause dangerous brain bleeding. In 2005, Griffin et al proposed using Activated Protein C in conjunction with tPA to protect the brain from tPA’s harmful side-effects. APC activates protease-activated receptor 1 (PAR-1), which plays a role in the interaction of coagulation and inflammation. The 3K3A-APC was designed to have more activity at protease-activated receptor 1 (PAR-1) and less anticoagulative effect than activated protein C. The phase 2 trial, RHAPSODY, was performed in the lab of Berislav Zlokovic, the scientific founder of ZZ Biotech, to determine safety and tolerability of the drug. A phase 3 $30 million trial, RHAPSODY-2, was planned to determine safety and efficacy for treatment of ischemic stroke. However, on November 16, 2023, the National Institutes of Health (NIH) paused the start of the human trial of 3K3A-APC after an investigation by Science Magazine.
Sources: en.wikipedia.org
{\displaystyle {\ce {{^{238}_{92}U}+{}_{0}^{1}n->{}_{92}^{239}U->[\beta ^{-}][23.5\ {\ce {min}}]{}_{93}^{239}Np->[\beta ^{-}][2.3\ {\ce {days}}]{}_{94}^{239}Pu}}\left({\ce {->[\alpha ][2.4\cdot 10^{4}\ {\ce {years}}]}}\right){\ce {^{235}_{92}U}}}
== Into a vacuum == Effusion from an equilibrated container into outside vacuum can be calculated based on kinetic theory. The number of atomic or molecular collisions with a wall of a container per unit area per unit time (impingement rate) is given by:
(2026) study the visibility of fallow deer in broad-leaved woodland environment, and interpret purported hunting lesions on fossil bones of fallow deer as placed in areas that would be visible to Palaeolithic hunters in such environments. Evidence indicating that Aurignacian artifacts from cave sites in southwestern Germany were adorned with geometric sign sequences of comparable complexity to that of early proto-cuneiform is presented by Bentz & Dutkiewicz (2026). Conard, Janas & Zeidi (2026) report the discovery of two Aurignacian bird figurines made from mammoth ivory in the Hohle Fels cave (Germany). Isle de Beauchaine et al. (2026) study the morphology of teeth in the Aurignacian mandible Les Rois 2 from the Les Rois cave (Charente, France), interpreted as consistent with assignment of the specimen to an anatomically modern human. Röding et al. (2026) study the morphology of the Late Pleistocene frontal bone from Hahnöfersand (Germany) described by Bräuer (1980), interpret it as falling within the variability of Holocene Homo sapiens, and find no evidence of a morphology intermediate between those of Neanderthals and modern humans. Bossoms Mesa et al. (2026) report evidence of preservation of human DNA in pigment samples collected in and around Paleolithic rock art, including preservation of DNA resulting from deposition through direct human contact in the Escoural Cave (Portugal).
Hypomobility is reduced range of motion in one or more joints relative to what is considered normal. It may arise from structural, neurological, inflammatory, or functional causes, and may be temporary or chronic depending on the underlying condition. Hypomobility is commonly assessed in clinical contexts such as musculoskeletal medicine, physiotherapy, and rheumatology.
=== Biosynthesis and attachment === Most endogenously produced RLA are not "free" because octanoic acid, the precursor to RLA, is bound to the enzyme complexes prior to enzymatic insertion of the sulfur atoms. As a cofactor, RLA is covalently attached by an amide bond to a terminal lysine residue of the enzyme's lipoyl domains. The precursor to lipoic acid, octanoic acid, is made via mitochondrial fatty acid biosynthesis in the form of octanoyl-acyl carrier protein. The octanoate is transferred as a thioester of acyl carrier protein from mitochondrial fatty acid biosynthesis to an amide of the lipoyl domain protein by an enzyme called an octanoyltransferase. Two hydrogens of octanoate are replaced with sulfur groups via a radical SAM mechanism, by lipoyl synthase. As a result, lipoic acid is synthesized attached to proteins and no free lipoic acid is produced. Lipoic acid can be removed whenever proteins are degraded and by action of the enzyme lipoamidase. Free lipoate can be used by some organisms as an enzyme called lipoate protein ligase that attaches it covalently to the correct protein. The ligase activity of this enzyme requires ATP.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.